10109939Next-generation lentiviral production to enable advanced therapies including CAR-T immunotherapy for childhood malignanciesClosedCollaborative R&DInnovate UKChimeric antigen receptor (CAR) T-cell immunotherapies have transformed patient outcomes for blood-borne cancers. Most vector for commercial CAR-T is lentivirus, which is used to modify T-cells _ex vivo_ prior to their reinfusion into the patient. However, high manufacturing and treatment costs and rising safety concerns threaten to derail the advanced therapeutics revolution. _In vivo_ CAR T-cell therapy, where the T-cell is reprogramed directly in the patient's body, is an emerging experimental approach that could address these concerns. However, current lentivirus manufacturing suffers from breakthrough payload expression, resulting in insufficient precision to target circulating T-cells. This would be absolutely required for such a treatment modality. Lentitek have developed a unique vector that reduces such breakthrough expression. The project further validates this powerful new tool with project partner University College London (UCL). Lentitek will leverage the results to commercialise the technology, leading to better patient safety, increased industrial competitiveness, and democratised cancer immunotherapy in under-served patient populations including paediatric cancer patients.